China's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength

CANbridge Pharmaceuticals

31/08/2026 05:33

Overview
China rare disease drugmaker's H1 revenue rose 25.6% yr/yr, driven by Hunterase and Livmarli sales
Company reported progress in drug pipeline and business operations during the reporting period
Research and development expenses fell 30.5%, mainly due to lower operational costs and project timing

Outlook
Company did not provide specific guidance or forecasts for future quarters or full year in the press release

Result Drivers
HUNTERASE AND LIVMARLI SALES - Co said revenue growth was mainly driven by increased sales of Hunterase and Livmarli
LOWER R&D EXPENSES - Co said research and development expenses fell due to lower operational costs and timing of clinical trials
LEASE TERMINATION GAINS - Co recognized gains from early termination of US lease property, credited to profit for the period

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 27.9 mln
 

Reuters Recommended Reads
Aug 28 - China's Dawnrays Pharmaceutical H1 revenue falls on lower procurement prices 
Aug 28 - China's Joinn Laboratories H1 profit jumps 1,127% on strong drug demand
Aug 28 - US FDA approves Takeda, Protagonist's drug for rare blood cancer

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)